Business

Know the Business — Partners Group Holding AG

Bottom line. Partners Group is a Swiss-listed, asset-light private-markets toll collector: it builds bespoke multi-asset private-markets portfolios for institutions and wealth clients, charges a stable ~1.24% management fee on USD 185 billion of AuM, plus carry, and converts that into a 60% EBIT margin and a 55% ROE that almost no listed asset manager outside the alts cohort can match. The market is most likely underestimating the durability of the bespoke-mandate moat and the wealth-channel runway, and most likely overestimating how soon performance fees will normalize to a steady-state mix. At the FY2025 share price (CHF 982) the stock trades on ~20x earnings and a 4.3% dividend yield, the cheapest end of its 10-year range, but earnings are cycle-fattened by a one-year +60% performance-fee snapback.

1. How This Business Actually Works

Partners Group is not a fund. It is a fee-collecting platform built on long-dated client commitments. Clients — pension plans, insurers, sovereigns, and increasingly wealth platforms — hand the firm capital with multi-year (often perpetual) contracts. Partners Group invests across four private-markets asset classes, and earns three revenue streams: an annuity management fee on AuM, a back-end performance fee on profits, and a small balance-sheet line from co-investing alongside clients. Revenue scales with AuM, marginal cost of the next dollar of AuM is close to zero once the platform exists, and roughly 60% of incremental fees drop to EBITDA.

Two features explain almost everything else.

The fee margin barely moves. Across the FY2015–FY2025 decade — through a 2018 sell-off, COVID, zero rates, a 2021 mega-cycle, the 2022–24 fundraising downturn, and a 2025 partial recovery — the management-fee margin stayed inside a 1.18–1.33% band. LPs are not negotiating PGHN down on price (clients pay for the bespoke-portfolio-construction service, not just the fund), and mix shifts between strategies and structures roughly offset.

Performance fees are the call option, not the engine. Management fees grew +7% in 2025 in reported CHF and ~+12% on constant currency. Performance fees grew +60% in the same year (CHF 819m, 32% of revenue, vs 24% in 2024). The first line is what compounds with the franchise; the second line is what makes any given year look great or terrible. Management guides the performance-income share to settle into a 25–40% band — a typical year is closer to 30% than to 32%. Pay for the annuity; treat the carry as upside in good vintages.

Cost structure is 90% people and offices. Bargaining power vs LPs is moderate and asymmetric: high in good vintages (mandate clients have already integrated PGHN into their portfolio plumbing — switching is operationally painful), lower in slow vintages when LPs squeeze on side-letter rights. Bargaining power vs portfolio companies is structural: PGHN owns or controls them. Bargaining power vs distribution is the one to watch — every wealth-channel partnership is a multi-year AuM tailwind, but PGHN must share economics with the platform.

2. The Playing Field

PGHN sits mid-pack by scale but at the top of the table on operating economics. The US giants (Blackstone, KKR, Apollo) are 4–8x larger by AuM and 4–5x larger by market cap, but they earn their revenue through different mixes: BX and KKR carry large insurance balance sheets, APO is two-thirds credit/insurance, BAM is real-assets-heavy. PGHN's three closest economic comparables are EQT (European private-markets pure-play, same four buckets), Hamilton Lane (bespoke private-markets solutions provider — closest match for the mandate business), and Bridgepoint (smaller European PE/credit GP). The big US alts are scale benchmarks, not direct comps.

Sources: Yahoo Finance market caps (May 2026); AuM from latest FY2025 filings. KKR EBIT margin marked "n/m" because consolidated revenue includes Global Atlantic insurance net premiums that distort the gross-margin line.

Three things stand out:

PGHN earns the highest EBIT margin of any listed alt and the market is paying the lowest P/E for it. Only Hamilton Lane has a comparable margin/multiple combination, and HLNE is a tenth the size. The dispersion is not about earnings quality — it is about growth (management fees in CHF are growing slower than at BX in USD) and about the 2025 stock fell 20% on guidance reset and FX.

The Hamilton Lane comp is the most informative. HLNE runs a bespoke-solutions model closest to PGHN's mandate business, has a comparable 43% EBIT margin and 32% ROE, and trades at 17x earnings — barely above PGHN.

The big US alts dominate scale, not unit economics. BAM has 23% ROE on USD 1,075bn AuM — three times the FpAuM but half the return on equity, because real-assets dollars carry lower fee margins. Apollo's 22% EBIT margin is depressed by insurance accounting; KKR's headline 4% operating margin is meaningless once Global Atlantic is backed out. PGHN's 60% EBIT and 55% ROE are the cleanest in the cohort precisely because there is no insurance subsidiary.

What good looks like in this peer set:

• A 60%+ EBIT margin (PGHN, BX) signals a genuinely fee-driven, disciplined firm rather than one buying revenue with balance-sheet leverage.
• 30%+ ROE with no insurance subsidiary (PGHN, BAM, HLNE) is hard to fake.
• The ratio of bespoke-and-evergreen AuM to traditional closed-end AuM is the real moat indicator. PGHN's 67/33 is the highest in the listed cohort; BX is moving the same direction with BREIT/BCRED/BXPE.

3. Is This Business Cyclical?

Cyclical at the earnings line, much less so at the management-fee line, barely at all at the AuM line. That separation is the central feature of how to value private-markets GPs.

The total-revenue line zigzags. The management-fee line just climbs. Two cycles illustrate the difference:

2020 COVID year: total revenue fell ~12% as performance fees collapsed 58% (carry crystallizations froze when exits froze). Management fees still grew 2%. EBIT margin held at 62%. Profit fell 13%, not 50%.

2021 mega-cycle: the realization window flew open. Performance fees jumped from CHF 157m to CHF 1.16bn — 7x in one year. Revenue jumped 86% and EPS nearly doubled. Then 2022 brought the mean-reversion: performance fees collapsed 70%, revenue fell 29%, EPS dropped 29%. Anyone capitalizing 2021 earnings discovered the meaning of "ate at the top of the cycle."

2022–2024 fundraising drought: industry-wide fundraising fell ~31% from 2021 peak. PGHN's revenue and EPS held flat-to-mildly-growing the whole way — management fees grew with AuM (USD 127bn at end-2021 to USD 152bn at end-2024 despite the macro), and performance fees normalized to a low base instead of disappearing.

2025 partial reopening: realizations +47%, performance fees +60%, total revenue +20%. CHF appreciation against USD/EUR ate most of the reported management-fee growth (reported +7%; constant-currency +12%).

Performance fees and EPS are cyclical, AuM and management fees are secular. Discounting earnings using the recent five-year average (and not 2021 or 2022 alone) gives a reasonable normalized number — and that is the lens management is formalising by guiding performance income to 25–40% of revenue across cycles.

4. The Metrics That Actually Matter

For PGHN the metrics that decide value creation are AuM growth and its quality, the fee margin, the bespoke share of inflows, the EBIT margin, and the dividend / ROE on a stable equity base.

What is consistent (fee margin, bespoke share, EBIT margin — all stable at "strong") and what is genuinely cyclical (performance-fee mix, AuM growth). The strong+stable rows are the value drivers. The cyclical rows tell you when to buy or trim.

Three additional signals worth watching: (1) gross new client assets vs tail-downs in each half-yearly trading update — the leading indicator for revenue 12–18 months out; (2) wealth-channel inflows as a percentage of fundraising — currently growing but still under-disclosed; and (3) management-fee EBITDA as a separate line (CHF 1,090m in FY25 vs CHF 1,033m in FY24, +6%) — the underlying recurring earnings stripped of cycle effects.

5. What Is This Business Worth?

The right valuation lens is earnings power on a normalized fee mix, plus a residual option on the realization cycle. It is not sum-of-the-parts — the four asset classes share the same employees, same balance sheet, same platform, and PGHN does not list any subsidiary or own a separately-valued insurance business. It is also not P/B — the equity is small (CHF 2.2bn) relative to the franchise value. The cleanest lens is P/E on through-cycle EPS with explicit treatment of the management-fee vs performance-fee mix, cross-checked by dividend yield given the 95% payout ratio.

At year-end 2025 the stock trades on 20.3x trailing earnings, 16.0x EV/EBITDA, and a 4.3% dividend yield — the cheapest end of its decade-long range. Three years ago in the 2022 trough, the same multiples were near-identical (20.9x, 17.2x, 4.1%). The catch in 2025 is that performance fees have already recovered; the cheapness is on a fattened earnings base. Normalize the 32% performance-fee share to a 28% mid-point and the through-cycle multiple is closer to ~22x — still below the 25x 10-year median.

How to underwrite this business:

• Pay for the annuity at a high-quality compounder multiple (high-teens to low-20s P/E) on management-fee EBITDA.
• Add a small option value for performance fees rather than capitalizing the current crystallization rate.
• Treat the dividend yield as a soft floor — at 95% payout and 19 unbroken years of growth, it would take franchise-level deterioration to break.
• Don't try to SOTP — every PGHN dollar of AuM goes through the same platform, the same fee, the same cost base.

The valuation case depends on three conditions: whether AuM compounding to USD 450bn by 2033 is achievable at the current fee margin; whether the wealth-channel partnerships (BlackRock-Morgan Stanley, Deutsche Bank, PGIM, Generali) become meaningful; and whether the management-fee margin holds against platform fee-sharing. If all three hold, the stock is cheap; if institutional fundraising stays muted, wealth channels disappoint, and the management-fee margin slips toward 1.10%, it is not.

6. What I'd Tell a Young Analyst

Watch the management fee, ignore the noise. Performance fees move the print and move the stock — but they are the residual, not the engine. The single most informative line in every half-yearly report is management-fee EBITDA growth. Compound at low double digits and the equity compounds regardless of what carry does in any given year. Drop below high-single digits for two years in a row and the franchise is fading.

The bespoke share is the moat. Track it every report. When mandates+evergreens hold above 70% of inflows, PGHN is winning the "scale plus customization" trade the US giants cannot copy at PGHN's price point. Drift toward 60% means traditional LP fundraising has come back at the expense of the differentiated solutions business — at which point the multiple would deserve to converge toward EQT/Carlyle, not Hamilton Lane/Blackstone.

The wealth-channel narrative is real, but slow. ELTIF 2.0, the BlackRock-Morgan Stanley SMA, the Deutsche Bank evergreen — these are 3–5 year build-outs, not next-quarter catalysts.

The market is most likely missing: that management-fee compounding is more durable than the cyclical headline suggests, and that CHF reporting distorts the underlying USD/EUR growth of the franchise (constant-currency mgmt fees grew 12% in 2025 vs reported 7%). It is most likely over-believing: that the FY2025 32% performance-fee share is the new run-rate.

What would change the thesis: (1) a sustained drop below 60% in the bespoke share of fundraising; (2) a fee-margin slip below 1.15% — wealth-platform partners extracting too much economics; (3) a dividend cut — never cut in 19 public years, so the day it does is the day the moat broke; (4) a CHF break-out vs USD/EUR materially above current levels that compresses reported margins for an extended period; (5) Grizzly-style mark allegations whose substance is not refuted with quarterly external NAV evidence.

The simple takeaway: PGHN is the cleanest, highest-margin, most differentiated mid-sized European listed alt — priced at the cheapest end of its decade. The bull case is the bespoke moat plus wealth channels compounding for a decade. The bear case is that 2025 is the cyclical top and CHF strength masks underlying fee-margin pressure. Track three numbers every six months — management fee growth in constant currency, the bespoke share, and the EBIT margin — and the asset stories that fill the annual report become texture, not signal.